Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849163 | 1.00 | DRD2 (0.56) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL2390523 | 0.88 | DRD2 (0.49) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL31206080 | 0.88 | DRD2 (0.49) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL25039624 | 0.88 | DRD2 (0.49) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL2390531 | 0.88 | DRD2 (0.49) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL25039653 | 0.88 | DRD2 (0.49) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL23826798 | 0.87 | CRHR1 (0.54) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL23826796 | 0.87 | CRHR1 (0.54) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL31206158 | 0.84 | DRD2 (0.47) | DRD2KDM1AMAOBCRHR1DRD3 | |
| SCHEMBL30324560 | 0.84 | KMT2A (0.55) | DRD2KDM1AMAOBDRD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8614213-B2 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| CN-102143940-A | Cyclohexyl amide derivatives as CRF-1 receptor antagonists and uses thereof | NOVARTIS AG | 2011-08-03 | — | — | CN | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | DRD2 282/4885KDM1A 3844/4885MAOB 409/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | DRD2 241/4885KDM1A 3961/4885MAOB 391/4885 |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | CRHR1, CRH, CRHR2 | DRD2 294/4885KDM1A 2912/4885MAOB 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.